Navigate Fool.com
Will DNDN beat
the market?

Dendreon Corp


Community Rating: 2 Stars: Unattractive

2.69 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.71
Previous Close $2.69
Daily Range $2.66 - $2.75
52-Week Range $2.23 - $5.38
Market Cap $427.6M
P/E Ratio -1.38
Dividend (Yield) $0.00 (0.0%)
Volume 2,244,867
Average Daily Volume 3,006,502
Current FY EPS -$0.88

How do you think DNDN
will perform against the market?

Top DNDN Bull/Bear Pitches


zzlangerhans (< 20)
Submitted August 5, 2011

Wow. I haven't followed Dendreon closely since I predicted incorrectly that their repeat phase III trial of Provenge would fail. I maintained some skepticism about the commercial potential of Provenge … More

0 Replies Reply Report this Post

DarthMaul09 (< 20)
Submitted November 5, 2011

Medication formularies are more likely to contract as profit margins for insurance companies fall. Independent of how potentially beneficial a new drug may initially appear, there will be a slow acce … More

0 Replies Reply Report this Post

News & Commentary

5 Innovations Wall Street and Investors Don't Understand How to Value

Innovation is the cornerstone to any successful business. However, Wall Street and investors don't have the slightest clue what the true valuation of these five innovations should be.

Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View

Who Bucked the Short Interest Trend in Biotech Stocks?

5 Biotechs With Prostate Cancer Treatments Worth Watching

Prostate cancer is now the second leading cause of cancer-specific deaths among men in the United States. Here are five biotechs aiming to meet this challenge with a diversity of promising new therapies.

Why I Bought Exelixis

The author shares his opinion why the recent drop in Exelixis is an incredible buying opportunity.

Short Sellers Find Renewed Interest in Biotech Stocks

Cancer Vaccines: Doomed to Fail?

Another cancer vaccine comes up short in a pivotal study, casting doubt on the approach as a whole.

Medivation, Inc: Fast Growing Drugs That May Become Blockbusters

Medivation (MDVN) may see sales of its prostate cancer drug Xtandi hit a blockbuster run rate this year.

Short Sellers Retreat From Biotech Stocks Again

Biotech Earnings Checkup: CLDX, DNDN, OPX

Notable earnings reports in biotech this week.

See More DNDN News...





Dendreon Corp (DNDN) Description

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. Website: http://www.dendreon.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks